Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol hydrochloride solution for inhalation in lower respiratory tract infection with viscous sputum
CTR20211657Phase 3Completed
- Sponsor
- Sinopharm Guorui Pharmaceutical
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambroxol in acute bronchitis, chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD), pneumonia, pulmonary infection, sponsored by Sinopharm Guorui Pharmaceutical. Started Jul 2021; status: completed.
02
Drugs
ambroxol
03
Conditions
acute bronchitischronic bronchitis (CB)chronic obstructive pulmonary disease (COPD)pneumoniapulmonary infection
Beyond the preview
Go deeper on CTR20211657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211657.